QHSLab Inc Stock Price, News & Analysis

QHSLab (OTCQB: USAQ) has started a formal process to expand its board by adding independent directors as part of a governance overhaul aimed at strengthening oversight and supporting future growth and potential uplisting. The company said it has begun meetings and interviews with candidates and expects to provide updates as the selection progresses. This governance step follows corporate actions to simplify capital structure, including substantial elimination of legacy convertible debt, reduced interest expense, and a recent funding transaction described as supporting growth while limiting dilution. Management presented the changes as improving transparency, aligning interests, and positioning the company for next‑phase objectives.

QHSLab (OTCQB: USAQ) provided an unaudited financial and operational update ahead of a January 6, 2026 investor session. For the nine months ended September 30, 2025 the company reported $1.99 million in revenue, a 32% year-over-year increase, with $1.32 million gross profit and an approximate 66% gross margin. Net operating income before interest was $95,738.

At December 31, 2025 the company reported approximately $630,000 cash. Convertible debt was reduced from about $1.4 million to $20,000, which the company says should lower annual interest expense by more than $250,000. Outstanding shares total 13,418,899 with a public float of about 2,429,525 and ~2,301,565 restricted shares subject to Rule 144.

Management said it exited 2025 in a cash-flow-positive operating position and expects to report net income after interest, amortization, and depreciation for 2025, subject to year-end close and audit.

QHSLab (OTCQB: USAQ) completed a $500,000 private placement of common stock and long‑term warrants on Dec 29, 2025, after repurchasing and retiring more than $1.4 million of legacy convertible notes. The retired notes carried 18% default interest and conversion rights at $0.20 per share; their retirement eliminated several million shares of potential dilution and reduced interest expense by more than $200,000 annually. The company says the combined actions improve liquidity and financial flexibility to support working capital, targeted sales and marketing, onboarding capacity, and customer support as it pursues recurring revenue growth in digital medicine.

QHSLab reported $1.99M revenue for the first nine months of 2025 (+32% YoY) and $1.32M gross profit (66% margin).

QHSLab (OTCQB:USAQ) on Dec. 3, 2025 launched Q-Cog™, a cloud-based digital cognitive assessment for primary care to identify Mild Cognitive Impairment and dementia risk earlier.

An initial real-world pilot of 168 patients aged 65+ identified 90 patients (54%) at high risk and enabled real-time telemedicine referrals. Q-Cog™ combines cognitive, behavioral, and functional screening in one workflow and is presented as aligning with CMS Annual Wellness Visit requirements, supporting documentation for neurocognitive and behavioral health CPT codes and Risk Adjustment Factor (RAF) scoring.

QHSLab (OTCQB: USAQ) has launched its innovative Pediatric Health Assessment tool with a major pediatric group in Texas. This digital screening solution uniquely integrates behavioral health screening with allergy and asthma control metrics, addressing the connection between immune and mental health in children.

The assessment combines evidence-based behavioral health screeners (PSC-17 and SDQ Prosocial scale) with allergy control metrics (CARAT), creating a comprehensive evaluation platform. The tool screens for anxiety, depression, ADHD, sleep issues, and physical health factors, enabling pediatricians to provide more precise care during back-to-school checkups.

QHSLab has received IRB exemption for observational research to study the tool's population health impact, particularly focusing on the relationship between allergy management and behavioral screening results. This initiative positions the company for potential collaborations with pharmaceutical companies, payers, and public health systems.

QHSLab Inc. (OTCQB: USAQ) has launched its first co-branded QHS Behavioral Healthcare Center (QBHC) in Miami, marking a strategic collaboration with Global Behavioral Healthcare Group Corp. The center combines QHSLab's digital health platform with on-site behavioral health services to improve mental healthcare access and delivery.

The facility integrates QHSLab's comprehensive digital medicine tools, featuring AI-enhanced decision support, intelligent automation, and workflow optimization. The initiative represents a hybrid care model that connects digital screening technology with in-person psychiatric services, creating new revenue streams through brand and clinical process licensing while maintaining patient engagement.

QHSLab announced the publication of two peer-reviewed studies validating their digital health assessment tools. The first study, published in the Journal of Psychosomatic Research, demonstrates that patients with allergic rhinitis who seek help experience improved mental health outcomes. The second study in Consultant360 introduces the Q-Scale, a tool for predicting healthcare overutilization. CEO Troy Grogan emphasized these studies validate QHSLab's position in mental health, preventative screening, and AI-supported care. The company's digital solutions support CPT-coded reimbursable services, enabling new revenue streams for primary care practices while improving patient outcomes through early detection and personalized care approaches.

QHSLab Inc. (OTCQB: USAQ) announced it is in advanced discussions with Catheter Precision, Inc. regarding a strategic debt restructuring of its OID Notes. The proposed restructuring aims to improve the company's financial flexibility and reduce dilution pressure by increasing the conversion price of existing debt instruments. Key features include the introduction of a payment-in-kind (PIK) interest option and extension of note maturity.

The agreement, expected to be finalized in the coming weeks, would consolidate and extend existing obligations, reduce near-term payment obligations, and remove default-related overhang. This restructuring would allow QHSLab to redirect capital toward key growth initiatives in its digital health business.

QHSLab Inc. (USAQ) reported strong financial results for Q1 2025, with total revenue increasing 32.1% year-over-year to $645,419, up from $488,587 in Q1 2024. The company's gross profit rose to $429,944, with gross margin expanding to 66.6% from 58.6% in the prior year.

The growth was driven by multiple revenue streams, including a 28% increase in Integrated Service Program (ISP) revenue to $162,502, an 11.7% increase in Allergy Diagnostic Kit sales to $264,913, and new revenue of $89,100 from clinical study performance obligations. The improved gross margin reflects favorable product mix and operational synergies across the company's core offerings in digital health and diagnostic tools for primary care.

While most segments showed growth, subscription revenue declined by 49.5% to $9,285. The company expects continued variability in gross margin depending on product mix and pricing but maintains its focus on long-term profitability and scale.